Literature DB >> 6850589

Cell surface-mediated cytotoxicity of polymer-bound Adriamycin against drug-resistant hepatocytes.

K E Rogers, B I Carr, Z A Tökés.   

Abstract

Growth inhibition properties of Adriamycin-coupled polyglutaraldehyde microspheres have been assessed using a highly resistant rat liver cell line, RLC. Covalent attachment of Adriamycin to microspheres increased the cytostatic activity of the drug 1000-fold for this cell line as measured by 50% inhibitory concentration determinations. The effects of Adriamycin-polymer complexes were investigated and compared to free drug, using trypan blue dye exclusion and 51Cr release as indicators of cell viability. When carcinogen-altered drug-resistant rat hepatocytes were tested at an Adriamycin concentration of 10(-6) M, the polymer-bound drug killed 32% of the cells, while the free drug had no detectable cytotoxic effect. However, with normal rat hepatocytes at the same drug concentration, the Adriamycin-coupled microspheres were shown to be less toxic than free drug at 24 hr. It was demonstrated that greater than 99.5% of the drug remains covalently coupled to the microspheres throughout the experiments. Scanning electron micrographs are presented for both cell types, which demonstrate the effects of free and bound Adriamycin on the ultrastructure of the cell surface. The cells lose their microvilli, exhibit numerous blebs, and develop holes and pits in the surface. Transmission electron microscopy demonstrates that less than 1% of the microspheres is internalized by either cell type. Multiple interactions of the drug-polymer complexes with the cell surface are presented as the most probable explanation for the results.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850589

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

Review 3.  Sequence specificities in the interactions of chemicals and radiations with DNA.

Authors:  R J Wilkins
Journal:  Mol Cell Biochem       Date:  1984-09       Impact factor: 3.396

4.  Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate.

Authors:  E Monti; L Paracchini; F Piccinini; V Malatesta; F Morazzoni; R Supino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Nitrogen mustard interference with potassium transport systems in Ehrlich ascites tumor cells.

Authors:  W Doppler; J Hofmann; H Oberhuber; K Maly; H Grunicke
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.

Authors:  T G Burke; A C Sartorelli; T R Tritton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Fluorescence depolarization measurements on oriented membranes.

Authors:  M Adler; T R Tritton
Journal:  Biophys J       Date:  1988-06       Impact factor: 4.033

9.  Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia.

Authors:  B Vayuvegula; L Slater; J Meador; S Gupta
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation.

Authors:  M Panneerselvam; R Bredehorst; C W Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.